<DOC>
	<DOC>NCT00764270</DOC>
	<brief_summary>The purpose of this study is to see if a dietary supplement, R-alpha lipoic acid, is able to reduce risk factors in people with documented heart disease and increased levels of inflammation.</brief_summary>
	<brief_title>The Role of R-Alpha Lipoic Acid in the Treatment of Atherosclerotic Vascular Disease</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Thioctic Acid</mesh_term>
	<criteria>Documented congestive heart disease (CHD)(defined as at least one significant coronary stenosis &gt; 50% on angiography, or history of documented myocardial infarction) Not diagnosed with unstable angina, uncontrolled hypertension, heart failure, recent myocardial infarction (within last six months) Not taking insulin or oral hypoglycemic agents, antiinflammatory drugs other than aspirin, or hormone replacement therapy On stable doses for four weeks prior to entry of lipidlowering therapy (statins), aspirin, and angiotensinconverting enzyme inhibitors or other blood pressure medications. P No tobacco use within 3 months of the study No laboratory evidence of renal, hepatic, or hematological abnormalities Not currently taking vitamin or antioxidant supplements, including Ralpha lipoic acid, except standard multivitamin/mineral supplements containing not more than the Daily Value (DV) of the vitamins and minerals; Elevated levels of urinary and plasma F2isoprostanes Elevated plasma levels of hsCRP</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>atherosclerosis</keyword>
	<keyword>lipoic acid</keyword>
	<keyword>thioctic acid</keyword>
	<keyword>triglycerides</keyword>
	<keyword>overweight</keyword>
	<keyword>obesity</keyword>
	<keyword>oxidative stress</keyword>
	<keyword>inflammation</keyword>
</DOC>